Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 29:12:691536.
doi: 10.3389/fimmu.2021.691536. eCollection 2021.

Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis

Raquel Ruiz-García  1   2 , Guillermo Muñoz-Sánchez  1 , Laura Naranjo  1 , Mar Guasp  2   3   4 , Lidia Sabater  2 , Albert Saiz  2   3 , Josep Dalmau  2   3   4   5   6 , Francesc Graus  2 , Eugenia Martinez-Hernandez  2   3
Affiliations

Limitations of a Commercial Assay as Diagnostic Test of Autoimmune Encephalitis

Raquel Ruiz-García et al. Front Immunol. .

Abstract

Detection of neuronal surface antibodies (NSAb) is important for the diagnosis of autoimmune encephalitis (AE). Although most clinical laboratories use a commercial diagnostic kit (Euroimmun, Lübeck, Germany) based on indirect immunofluorescence on transfected cells (IIFA), clinical experience suggests diagnostic limitations. Here, we assessed the performance of the commercial IIFA in serum and CSF samples of patients with suspected AE previously examined by rat brain immunohistochemistry (Cohort A). Of 6213 samples, 404 (6.5%) showed brain immunostaining suggestive of NSAb: 163 (40%) were positive by commercial IIFA and 241 (60%) were negative. When these 241 samples were re-assessed with in-house IIFA, 42 (18%) were positive: 21 (9%) had NSAb against antigens not included in the commercial IIFA and the other 21 (9%) had NSAb against antigens included in the commercial kit (false negative results). False negative results occurred more frequently with CSF (29% vs 10% in serum) and predominantly affected GABABR (39%), LGI1 (17%) and AMPAR (11%) antibodies. Results were reproduced in a separate cohort (B) of 54 AE patients with LGI1, GABABR or AMPAR antibodies in CSF which were missed in 30% by commercial IIFA. Patients with discordant GABABR antibody results (positive in-house but negative commercial IIFA) were less likely to develop full-blown clinical syndrome; no significant clinical differences were noted for the other antibodies. Overall, NSAb testing by commercial IIFA led to false negative results in a substantial number of patients, mainly those affected by anti-LG1, GABABR or AMPAR encephalitis. If these disorders are suspected and commercial IIFA is negative, more comprehensive antibody studies are recommended.

Keywords: autoimmune encephalitis (AE); brain immunohistochemistry; diagnostic test; immunofluorescent assay; neuronal antibodies.

PubMed Disclaimer

Conflict of interest statement

JD receives royalties from Athena Diagnostics for the use of Ma2 as an autoantibody test and from Euroimmun for the use of NMDA, GABAB receptor, GABAA receptor, DPPX and IgLON5 as autoantibody tests. FG holds a patent for the use of IgLON5 as an autoantibody test. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with the authors FG and JD.

Figures

Figure 1
Figure 1
Antibody detection in patients from Cohort A. Workflow used to identify IgG neuronal surface antibodies in a cohort of 6231 samples. IIFA, Indirect immunofluorescent assay; NSAb, Neuronal surface antibodies.
Figure 2
Figure 2
Discrepancies identifying GABABR antibodies by IIFA. (A) One of the two patients’ CSF (P2) demonstrating GABABR immunoreactivity on rat brain immunohistochemistry. Hippocampus (left panel) and cerebellum (right panel) staining patterns. (B) Upper panels show patient 1’s CSF (P1) reactivity on commercial IIFA and in-house IIFA GABABR transfected cells; lower panels show patient 2’s CSF (P2) reactivity on commercial IIFA (negative staining) and in-house IIFA (positive staining) GABAbR transfected cells.
Figure 3
Figure 3
Discrepancies identifying LGI1 antibodies by IIFA. (A) A patient’s CSF demonstrating LGI1 immunoreactivity on rat brain immunohistochemistry. Hippocampus (left panel) and cerebellum (right panel) staining patterns. (B) Left panel shows patient’s CSF reactivity on commercial IIFA LGI1 transfected cells (negative staining); Right panels show CSF reactivity on in-house IIFAs using LGI1 plus ADAM23 transfected cells (upper panels; positive staining) and GPI-LGI1 transfected cells (lower panels, negative staining). GPI: glycosyl-phosphatidylinositol anchored LGI1 (to display the protein on the cell surface).
See this image and copyright information in PMC

References

    1. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. . A Clinical Approach to Diagnosis of Autoimmune Encephalitis. Lancet Neurol (2016) 15(4):391–404. 10.1016/S1474-4422(15)00401-9 - DOI - PMC - PubMed
    1. Dalmau J, Graus F. Antibody-Mediated Encephalitis. (2018) (Accessed 2019 Aug 15). - PubMed
    1. Ricken G, Schwaiger C, De Simoni D, Pichler V, Lang J, Glatter S, et al. . Detection Methods for Autoantibodies in Suspected Autoimmune Encephalitis. Front Neurol (2018) 9:841. 10.3389/fneur.2018.00841 - DOI - PMC - PubMed
    1. Gastaldi M, Zardini E, Scaranzin S, Uccelli A, Andreetta F, Baggi F, et al. . Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. Front Neurol (2020) 10:1385. 10.3389/fneur.2019.01385 - DOI - PMC - PubMed
    1. McCracken L, Zhang J, Greene M, Crivaro A, Gonzalez J, Kamoun M, et al. . Improving the Antibody-Based Evaluation of Autoimmune Encephalitis. Neurol Neuroimmunol Neuroinflamm (2017) 4(6):e404. 10.1212/NXI.0000000000000404 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts